S. Novello, F. Barlesi, R. Califano, T. Cufer, S. Ekman et al., Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann. Oncol, vol.27, pp.1-27, 2016.

E. Giroux-leprieur, C. Dumenil, C. Julie, V. Giraud, and J. Dumoulin, Immunotherapy revolutionises non-small-cell lung cancer therapy: results, perspectives and new challenges, Eur. J. Cancer, vol.78, pp.16-23, 2017.

D. Kazandjian, P. Keegan, D. L. Suzman, R. Pazdur, and G. M. Blumenthal, Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1. 1-defined disease progression in clinical trials, Semin. Oncol, vol.44, pp.3-7, 2017.

B. Melosky, Current Treatment algorithms for patients with metastatic non-small cell, non-squamous lung cancer, Front. Oncol, vol.7, p.38, 2017.

J. Brahmer, K. L. Reckamp, P. Baas, L. Crino, W. E. Eberhardt et al., Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N. Engl. J. Med, vol.373, pp.123-135, 2015.

H. Borghaei, L. Paz-ares, L. Horn, D. R. Spigel, M. Steins et al., Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N. Engl. J. Med, vol.373, pp.1627-1639, 2015.

E. B. Garon, N. A. Rizvi, R. Hui, N. Leighl, A. S. Balmanoukian et al., Pembrolizumab for the treatment of non-small-cell lung cancer, N. Engl. J. Med, vol.372, pp.2018-2028, 2015.

N. A. Rizvi, J. Mazieres, D. Planchard, T. E. Stinchcombe, G. K. Dy et al., Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial, Lancet Oncol, vol.16, pp.257-265, 2015.

R. S. Herbst, P. Baas, D. W. Kim, E. Felip, J. L. Perez-gracia et al., Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet, vol.387, pp.1540-1550, 2016.

B. P. Yawn, P. C. Wollan, C. Schroeder, L. Gazzuola, and M. Mehta, Temporal and genderrelated trends in brain metastases from lung and breast cancer, Minn. Med, vol.86, pp.32-37, 2003.

P. W. Sperduto, N. Kased, D. Roberge, Z. Xu, R. Shanley et al., Summary report on the Graded Prognostic Assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases, J. Clin. Oncol, vol.30, pp.419-425, 2012.

R. Soffietti, P. Cornu, J. Y. Delattre, R. Grant, F. Graus et al., EFNS guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force, Eur. J. Neurol, vol.13, pp.674-681, 2006.

T. Walbert and M. R. Gilbert, The role of chemotherapy in the treatment of patients with brain metastases from solid tumors, Int. J. Clin. Oncol, vol.14, pp.299-306, 2009.

R. Porta, J. M. Sanchez-torres, L. Paz-ares, B. Massuti, N. Reguart et al., Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation, Eur. Respir. J, vol.37, pp.624-631, 2011.

Y. L. Wu, C. Zhou, Y. Cheng, S. Lu, G. Y. Chen et al., Erlotinib as secondline treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803), Ann. Oncol, vol.24, pp.993-999, 2013.

G. Robinet, P. Thomas, J. L. Breton, H. Lena, S. Gouva et al., Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-smallcell lung cancer: groupe Français de Pneumo-Cancerologie (GFPC) Protocol 95-1, Ann. Oncol, vol.12, pp.59-67, 2001.

C. E. Mccoach, E. M. Berge, X. Lu, A. E. Baron, and D. R. Camidge, A brief report of the status of central nervous system metastasis enrollment criteria for advanced nonsmall cell lung cancer clinical trials: a review of the ClinicalTrials.gov Trial Registry, J. Thorac. Oncol, vol.11, pp.407-413, 2016.

E. Dudnik, S. Yust-katz, H. Nechushtan, D. A. Goldstein, A. Zer et al., Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases, Lung Cancer, vol.98, pp.114-117, 2016.

S. B. Goldberg, S. N. Gettinger, A. Mahajan, A. C. Chiang, R. S. Herbst et al., Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial, Lancet Oncol, vol.17, pp.976-983, 2016.